Co-Diagnostics Q3 EPS $(1.01) Beats $(1.25) Estimate, Sales $282.881K Beat $169.000K Estimate

Co-Diagnostics (OTC:CODX) reported quarterly losses of $(1.01) per share which beat the analyst consensus estimate of $(1.25) by 19.2 percent. This is a 78.96 percent increase over losses of $(4.80) per share from the same period last year. The company reported quarterly sales of $282.881 thousand which beat the analyst consensus estimate of $169.000 thousand by 67.39 percent. This is a 94.58 percent increase over sales of $145.380 thousand the same period last year.